The efficacy of Abiraterone Acetate treatment for patients with metastatic prostate cancer

Authors

  • Razan Hadidi جامعة دمشق
  • Moudar Bakkour

Keywords:

Abiraterone Acetat, castration, blockade, androgen, metastatic, proatate cacer

Abstract

Background & Aim: Patients with metastatic prostate cancer are treated with surgical or pharmacological castration with a high therapeutic response because testosterone is the primary growth  factor  for cancer cells. Later, when the relapse occurs after castration, anti-androgen therapy is treated to have a complete androgenic blockade. Anti-androgens are multiple types, and each pharmaceutical type has a different mechanism of action in preventing the manufacture of androgens.Patients with metastatic prostate cancer live longer as a result of many new treatments that prolong survival with good control of side effects and quality of life. Abiraterone prevents the production of androgens in the tumor, as well as in the testicles and adrenal glands by inhibiting the enzyme responsible for the manufacture of androgen. In our research, we will study  the efficacy  of Abiraterone  Acetate   in metastatic prostate cancer in patients who have received previous hormonal or chemical with hormonal treatments.

Materials and methods: a cross-sectional study of patients with metastatic prostate cancer admitted to al Bairuny university hospital. data collected included age, previously applied treatment lines, medical history, laboratory data, follow-up the effect of the applied treatment and evaluate its effectiveness and its relationship to previous disease.

Results: the case of 131 patients have been studied and examined the effectiveness of treatment, patients were followed for a whole year, and during this period, a clinical, laboratory and radial assessment every two months. As well as its relationship with previous therapeutic lines applicable and effective effect on the quality of life and the results are obtained and submitted and linked to previous studies.

conclusion: Abiraterone acetate is considered an important and effective line of treatment for patients with metastatic prostate cancer, especially because of its simply of administration in its oral form and its acceptance by patients, in addition to improving the quality of life, improving the degree of pain and controlling its limited side effects

Downloads

Download data is not yet available.

Downloads

Published

2022-10-07

How to Cite

The efficacy of Abiraterone Acetate treatment for patients with metastatic prostate cancer. (2022). Damascus University Journal for Medical Sciences, 38(3). https://journal.damascusuniversity.edu.sy/index.php/heaj/article/view/2077